Cell-based high-content screening (HCS) assays have become an increasingly attractive alternative to traditional in vitro and in vivo testing in pharmaceutical drug development and toxicological safety assessment. The time- and cost-effectiveness of HCS assays, combined with the organotypic nature of human induced pluripotent stem cell (iPSC)-derived cells, open new opportunities to employ physiologically relevant in vitro model systems to improve screening for potential chemical hazards. In this study, they used two human iPSC types, cardiomyocytes and hepatocytes, to demonstrate the potential of a variety of HCS assay combinations for testing the potential toxicity of chemicals and complex substances. The overall aim was to improve in vitro toxicity testing by reducing the time and cost of the assays while enhancing the mechanistic interpretation of the readouts so that confidence in animal replacement tests is improved.

To know more, read this article: http://www.genengnews.com/insight-and-intelligence/high-content-assay-multiplexing-for-toxicity-screening-in-induced-pluripotent-stem-cell-derived-cardiomyocytes-and-hepatocytes/77900591/